Effect of Sufentanil and Midazolam for reduction of Myoclonic movements

Comparison of Sufentanil and Midazolam for reduction of Myoclonic movements fallowing etomidate injection in candidate patients for ocular surgery

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201307164780N2

Enrollment

Registered

2013-07-25

Start date

2011-09-09

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myoclonic movements. Drug-induced myoclonus

Interventions

Intervention 1: First group is received sufentanil 0.2 µ/Kg. Intervention 2: Second group is received midazolam 0.3 mg/kg.

Treatment - Drugs

First group is received sufentanil 0.2 µ/Kg

Second group is received midazolam 0.3 mg/kg.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criterion: adult patients ASA??-??? who candidate for elective surgery. Exclusion criteria: patients with impaired adrenal function; sensitivity to drugs; mental disorders, neuromuscular disorders; seizures; and electrolyte abnormalities.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Myoclonus severity. Timepoint: At the end of the study. Method of measurement: According to Myoclonus Rating Scale into mild, moderate and sever.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mohammad Alipour

Mashhad University of Medical Sciences

Alipourm@mums.ac.ir+98 51 1801 2612

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026